Opinion – Trump declares opioid crisis a national emergency – CNN – John Gelmini


I tend to agree with Dr Alf that Trump’s behind the curve on opioids.

People take drugs for a reason, usually because they need to feel better about themselves and their lot or as a crutch to get through difficulties for which they cannot see a way out.

Those who are wealthy do so to fill a spiritual and mental void, which their lifestyle cannot address, some do it because it is fashionable and a few, like the so-called “Wolf of Wall Street”, did it so that he could telephone investors faster, so that he could satisfy his incredible greed for wealth and please his Wall Street bosses when he first started work.

Working in America carries with it an assumption that, come what may, you will deliver 10% more each year, will do so with a winning attitude, will never coast, will never be average.

The pressure is relentless and under it some people thrive, whilst others fall by the wayside through divorce, ill-health, financial mismanagement or being fired, unable to get work and other difficulties.

Trump’s state of emergency will deal with symptoms not these aspects of life in that country which if they are to be retained mean that people will have to be trained to a much higher level of mental toughness than they are now and become more able to build secondary income streams to sustain themselves during periods of financial difficulty.

Making divorce easier cheaper and faster might sound like a good idea but it is costly, causes young children under the age of seven to think they have done something wrong to bring the divorce about and it is damaging to productivity because people turn to drink and drugs to help themselves cope or are prescribed anti depressants by their doctors.

John Gelmini

EU should learn from Australia on drug approval process | EurActiv

This is an important read from EurActiv on pioneering fast-track drug approval processes.

via EU should learn from Australia on drug approval process | EurActiv.

I have always been a champion of effective innovation and in the drug industry the gains from faster product development are really important.

It seems that in both the US Europe, it is taking longer and is more costly to get new drugs approved. There are a number of spin-offs.

Firstly, as is taking longer for life-saving new drugs to reach approval, so more people are suffering.

Secondly, the extended approval process adds hugely to the cost of development and is making drug companies more risk averse.

Thirdly, the higher development costs often equates to higher prices, and increasingly state-of-the art drugs are excluded from public health care systems, for example, in the UK’s NHS.